Preservation Drug

**GCFLU Quadrivalent Multi PX**

*2021 Season*

**Split Virion, Influenza Vaccine**

**Description:**
GCFLU Quadrivalent Multi PX is a vaccine containing split virions of influenza A (H1N1) and A (H3N2) subtypes, B/Washington/02/2019, and B/Phuket/3073/2013.

**Active Ingredients:**
- Split Influenza A (H1N1) virus antigen (In-house) ........................................................... 120 µg
- A/Hong Kong/2671/2019 NIB-121(H3N2) ............................................................................. 30 µg
- B/Washington/02/2019 .......................................................................................................... 30 µg
- B/Phuket/3073/2013 .............................................................................................................. 30 µg
- Disodium hydrogen phosphate dihydrate .............................................................................................. 1.2 mg
- Potassium chloride ............................................................................................................................... 0.2 mg
- Sodium chloride ................................................................................................................................. 3.1 mg
- Lenalidomide phosphate dihydrate .......................................................................................................... 1.6 mg
- Water for Injection q.s.
- Thimerosal 0.01 w/v%

**Indications:**
- Prophylaxis against influenza caused by influenza A subtype viruses and type B viruses in persons aged 6 months and older.
- Treatment of influenza caused by influenza A subtype viruses and type B viruses in persons aged 6 months and older.

**Precautions in Administration:**
- Intravenous administration is prohibited.
- The injection site is usually lateral upper arm and disinfected with ethanol or tincture of iodine. Repeated injections at the same site should be avoided.
- Fever, headache, convulsions, dyskinesia and consciousness disorder usually occur within 2 weeks after the injection. If these symptoms persist, consult a physician quickly.
- The use of corticosteroids is not recommended for this vaccine.

**Contraindications:**
- Immunodeficiency caused by age or disease
- Hypersensitivity to egg, chicken, any other chicken component, and the product component.
- Person who showed Guillain-Barre syndrome within 6 weeks from the previous influenza vaccination or received any antiviral medication within 6 weeks.
- Pregnancy

**Drug Interactions:**
- Antibody reaction may not be sufficient in endogenous or iatrogenic immune deficient vaccinees.

**Adverse Drug Reactions:**
- Fever, headache, convulsions, dyskinesia and consciousness disorder usually occur within 2 weeks after the injection.
- Frequency, nature and seriousness of adverse drug reactions are similar regardless of the 2021 season or the previous season.

**Protection Drug**

**Table 1.**

<table>
<thead>
<tr>
<th>Race and Age</th>
<th>Subjects who had headache</th>
<th>Subjects who had fever</th>
<th>Subjects who had nausea and vomiting</th>
<th>Subjects who had arthralgia</th>
<th>Subjects who had chills</th>
<th>Subjects who had rash</th>
</tr>
</thead>
<tbody>
<tr>
<td>Elderly (65 years of age)</td>
<td>126 subjects (3.9%)</td>
<td>51 subjects (1.6%)</td>
<td>30 subjects (9.6%)</td>
<td>28 subjects (9.0%)</td>
<td>21 subjects (6.7%)</td>
<td>14 subjects (4.5%)</td>
</tr>
<tr>
<td>18-64 years</td>
<td>1265 subjects (64.6%)</td>
<td>515 subjects (25.3%)</td>
<td>305 subjects (15.5%)</td>
<td>285 subjects (14.5%)</td>
<td>215 subjects (10.6%)</td>
<td>145 subjects (7.4%)</td>
</tr>
<tr>
<td>6-17 years</td>
<td>1815 subjects (90.7%)</td>
<td>725 subjects (39.5%)</td>
<td>545 subjects (29.0%)</td>
<td>425 subjects (22.9%)</td>
<td>315 subjects (17.4%)</td>
<td>215 subjects (11.8%)</td>
</tr>
</tbody>
</table>

**Q & A**

1. **Who should receive the vaccine?**
   - Persons aged 6 months and older who are at high risk of developing serious complications from influenza.
   - Persons in close contact with persons who are at high risk of developing serious complications from influenza.

2. **What is the recommended age for vaccination?**
   - The recommended age for vaccination is 6 months and older.

3. **When should the vaccine be administered?**
   - The vaccine should be administered before the influenza season begins.

4. **What is the shelf life of the vaccine?**
   - The shelf life of the vaccine is 12 months from the date of manufacture.

5. **How is the vaccine stored?**
   - The vaccine should be stored at 2-8℃ without freezing.

6. **What are the indications for vaccination?**
   - Persons aged 6 months and older who are at high risk of developing serious complications from influenza.
   - Persons in close contact with persons who are at high risk of developing serious complications from influenza.

**Precautions in Administration:**
- Immunodeficiency caused by age or disease
- Hypersensitivity to egg, chicken, any other chicken component, and the product component.
- Person who showed Guillain-Barre syndrome within 6 weeks from the previous influenza vaccination or received any antiviral medication within 6 weeks.
- Pregnancy

**Adverse Drug Reactions:**
- Fever, headache, convulsions, dyskinesia and consciousness disorder usually occur within 2 weeks after the injection.
- Frequency, nature and seriousness of adverse drug reactions are similar regardless of the 2021 season or the previous season.

**Protection Drug**

**Table 1.**

<table>
<thead>
<tr>
<th>Race and Age</th>
<th>Subjects who had headache</th>
<th>Subjects who had fever</th>
<th>Subjects who had nausea and vomiting</th>
<th>Subjects who had arthralgia</th>
<th>Subjects who had chills</th>
<th>Subjects who had rash</th>
</tr>
</thead>
<tbody>
<tr>
<td>Elderly (65 years of age)</td>
<td>126 subjects (3.9%)</td>
<td>51 subjects (1.6%)</td>
<td>30 subjects (9.6%)</td>
<td>28 subjects (9.0%)</td>
<td>21 subjects (6.7%)</td>
<td>14 subjects (4.5%)</td>
</tr>
<tr>
<td>18-64 years</td>
<td>1265 subjects (64.6%)</td>
<td>515 subjects (25.3%)</td>
<td>305 subjects (15.5%)</td>
<td>285 subjects (14.5%)</td>
<td>215 subjects (10.6%)</td>
<td>145 subjects (7.4%)</td>
</tr>
<tr>
<td>6-17 years</td>
<td>1815 subjects (90.7%)</td>
<td>725 subjects (39.5%)</td>
<td>545 subjects (29.0%)</td>
<td>425 subjects (22.9%)</td>
<td>315 subjects (17.4%)</td>
<td>215 subjects (11.8%)</td>
</tr>
</tbody>
</table>

**Q & A**

1. **Who should receive the vaccine?**
   - Persons aged 6 months and older who are at high risk of developing serious complications from influenza.
   - Persons in close contact with persons who are at high risk of developing serious complications from influenza.

2. **What is the recommended age for vaccination?**
   - The recommended age for vaccination is 6 months and older.

3. **When should the vaccine be administered?**
   - The vaccine should be administered before the influenza season begins.

4. **What is the shelf life of the vaccine?**
   - The shelf life of the vaccine is 12 months from the date of manufacture.

5. **How is the vaccine stored?**
   - The vaccine should be stored at 2-8℃ without freezing.

6. **What are the indications for vaccination?**
   - Persons aged 6 months and older who are at high risk of developing serious complications from influenza.
   - Persons in close contact with persons who are at high risk of developing serious complications from influenza.

**Precautions in Administration:**
- Immunodeficiency caused by age or disease
- Hypersensitivity to egg, chicken, any other chicken component, and the product component.
- Person who showed Guillain-Barre syndrome within 6 weeks from the previous influenza vaccination or received any antiviral medication within 6 weeks.
- Pregnancy

**Adverse Drug Reactions:**
- Fever, headache, convulsions, dyskinesia and consciousness disorder usually occur within 2 weeks after the injection.
- Frequency, nature and seriousness of adverse drug reactions are similar regardless of the 2021 season or the previous season.

**Protection Drug**

**Table 1.**

<table>
<thead>
<tr>
<th>Race and Age</th>
<th>Subjects who had headache</th>
<th>Subjects who had fever</th>
<th>Subjects who had nausea and vomiting</th>
<th>Subjects who had arthralgia</th>
<th>Subjects who had chills</th>
<th>Subjects who had rash</th>
</tr>
</thead>
<tbody>
<tr>
<td>Elderly (65 years of age)</td>
<td>126 subjects (3.9%)</td>
<td>51 subjects (1.6%)</td>
<td>30 subjects (9.6%)</td>
<td>28 subjects (9.0%)</td>
<td>21 subjects (6.7%)</td>
<td>14 subjects (4.5%)</td>
</tr>
<tr>
<td>18-64 years</td>
<td>1265 subjects (64.6%)</td>
<td>515 subjects (25.3%)</td>
<td>305 subjects (15.5%)</td>
<td>285 subjects (14.5%)</td>
<td>215 subjects (10.6%)</td>
<td>145 subjects (7.4%)</td>
</tr>
<tr>
<td>6-17 years</td>
<td>1815 subjects (90.7%)</td>
<td>725 subjects (39.5%)</td>
<td>545 subjects (29.0%)</td>
<td>425 subjects (22.9%)</td>
<td>315 subjects (17.4%)</td>
<td>215 subjects (11.8%)</td>
</tr>
</tbody>
</table>